TY - JOUR

T1 - Pentoxifylline therapy in HIV seropositive subjects with elevated TNF

AU - Kruse, Alexandra

AU - Rieneck, Klaus

AU - Kappel, Mogens

AU - Orholm, Marianne

AU - Bruunsgaard, Helle

AU - Ullum, Henrik

AU - Skinhøj, Peter

AU - Pedersen, Bente Klarlund

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Tumor necrosis factor-α (TNF-α) is thought to induce cachexia in subjects infected with human immunodeficiency virus (HIV), and it has been suggested that HIV-seropositive patients would benefit from treatment with pentoxifylline, a known suppressor of TNF-α production. The purpose of the present study was to examine how pentoxifylline at a dose of 800 mg thrice daily would influence the cellular immune system in HIV-seropositive persons with elevated TNF-α. Six HIV-seropositive subjects with elevated amounts of TNF-α in plasma at least at two occasions were included in an open, controlled, randomized, cross-over study consisting of a 6 week treatment period and a 6 week control period. Blood samples were collected before and at the end of each period. Pentoxifylline treatment did not influence the concentration of plasma-TNF-α, subpopulations of blood mononuclear cells, the proliferative responses nor the natural killer (NK), and lymphokine activated killer (LAK) cell activities. Furthermore, pentoxifylline treatment did not influence the weight, temperature, well being, or tiredness of the subjects. However, the patients frequently reported gastrointestinal side effects. In vitro, however, pentoxifylline at suprapharmacological concentrations inhibited the blood mononuclear cell (BMNC) proliferative responses, NK, and LAK cell activities.

AB - Tumor necrosis factor-α (TNF-α) is thought to induce cachexia in subjects infected with human immunodeficiency virus (HIV), and it has been suggested that HIV-seropositive patients would benefit from treatment with pentoxifylline, a known suppressor of TNF-α production. The purpose of the present study was to examine how pentoxifylline at a dose of 800 mg thrice daily would influence the cellular immune system in HIV-seropositive persons with elevated TNF-α. Six HIV-seropositive subjects with elevated amounts of TNF-α in plasma at least at two occasions were included in an open, controlled, randomized, cross-over study consisting of a 6 week treatment period and a 6 week control period. Blood samples were collected before and at the end of each period. Pentoxifylline treatment did not influence the concentration of plasma-TNF-α, subpopulations of blood mononuclear cells, the proliferative responses nor the natural killer (NK), and lymphokine activated killer (LAK) cell activities. Furthermore, pentoxifylline treatment did not influence the weight, temperature, well being, or tiredness of the subjects. However, the patients frequently reported gastrointestinal side effects. In vitro, however, pentoxifylline at suprapharmacological concentrations inhibited the blood mononuclear cell (BMNC) proliferative responses, NK, and LAK cell activities.

KW - AIDS

KW - Cytokine

KW - HIV

KW - Lymphocyte

KW - Lymphokine activated killer cell

KW - Natural killer cell

KW - Pentoxifylline

KW - Proliferative response

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=0028788641&partnerID=8YFLogxK

U2 - 10.1016/0162-3109(95)00035-X

DO - 10.1016/0162-3109(95)00035-X

M3 - Journal article

C2 - 8655293

AN - SCOPUS:0028788641

VL - 31

SP - 85

EP - 91

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 1

ER -